Experimental triple combo for tough breast cancer shows early promise but trial stops short
NCT ID NCT04095689
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tested a combination of chemotherapy (docetaxel), an immunotherapy drug (pembrolizumab), and a gene therapy (IL-12) in 8 women with triple negative breast cancer that had stopped responding to standard anthracycline treatment. The goal was to see if the combination could shrink or eliminate tumors. The study was terminated early, so the full safety and effectiveness picture is not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
docetaxel, pembrolizumab, and interleukin-12 gene therapy
What this could lead to
If successful, this combination could offer a new treatment option for patients with hard-to-treat triple negative breast cancer that no longer responds to standard chemotherapy.
What could go wrong
This trial was terminated early with only 8 participants, so results are very limited. The combination of chemotherapy, immunotherapy, and gene therapy may cause significant side effects, and it is unclear if it works better than existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Houston Methodist Cancer Center
Houston, Texas, 77030, United States